The latest years have witnessed a growing interest towards the relationship between neuropsychiatric disease in children with autism spectrum disorders (ASD) and severe alterations in gut microbiota composition. In parallel, an increasing literature has focused the attention towards the association between derangement of the endocannabinoids machinery and some mechanisms and symptoms identified in ASD pathophysiology, such as alteration of neural development, immune system dysfunction, defective social interaction and stereotypic behavior. In this narrative review, we put together the vast ground of endocannabinoids and their partnership with gut microbiota, pursuing the hypothesis that the crosstalk between these two complex homeostatic systems (bioactive lipid mediators, receptors, biosynthetic and hydrolytic enzymes and the entire bacterial gut ecosystem, signaling molecules, metabolites and short chain fatty acids) may disclose new ideas and functional connections for the development of synergic treatments combining “gut-therapy,” nutritional intervention and pharmacological approaches. The two separate domains of the literature have been examined looking for all the plausible (and so far known) overlapping points, describing the mutual changes induced by acting either on the endocannabinoid system or on gut bacteria population and their relevance for the understanding of ASD pathophysiology. Both human pathology and symptoms relief in ASD subjects, as well as multiple ASD-like animal models, have been taken into consideration in order to provide evidence of the relevance of the endocannabinoids-microbiota crosstalk in this major neurodevelopmental disorder.

Keywords: gut-brain axis, microbiota, endocannabinoids, N-acyl-ethanolamines, autism spectrum disorders, microglia, immune system

1 ENDOCANNABINOIDS AND THE GUT MICROBIAL ECOSYSTEM

1.1 Endocannabinoids: A Brief Dip Into the Lipid Pot

In essence, endocannabinoids (eCBs) are bioactive lipid mediators that are produced from the common precursor arachidonic acid (ARA), and therefore belong to the family of polyunsaturated n-6 fatty acids (n-6 PUFAs) (Cascio, 2013; Bisogno and Maccarrone, 2014). eCBs exert pleiotropic actions and are able to regulate multiple biological functions, as demonstrated in neuropsychiatric
disorders (NPDs) (Navarrete et al., 2020) and in the regulation of body weight and feeding (Horn et al., 2018), by the way of their action as high-affinity ligands for specific G protein-coupled receptors (GPCRs) (Pertwee, 2015). N-arachidonoyl-ethanolamine [anandamide (AEA)] and 2-arachidonoylglycerol (2-AG) are well-studied eCBs that bind with high affinity type 1 and type 2 cannabinoids receptors (CB1 and CB2, respectively), two GPCRs. Together, the endogenous ligands (i.e., AEA and 2-AG), CB1/CB2 receptors and the enzymes accountable for eCBs synthesis

- [N-acyl-phosphatidylethanolamine-specific phospholipase D (NAPE-PLD) and diacylglycerol lipase (DAGL)-α and -β, for AEA and 2-AG respectively], degradation [fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), for AEA and 2-AG respectively], transport and, ultimately, eCBs concentration and tissue availability, give rise to the so-called eCB system (Mechoulam and Parker, 2013; Pertwee, 2015).

In turn, AEA and 2-AG are part of two larger lipid groups of eCBs-like molecules including N-acyl-ethanolamines (NAEs) and 2-acylglycerols (2-AcGs), respectively (Bisogno and Maccarrone, 2014; Di Marzo, 2018). NAEs and 2-AcGs share the common biosynthetic pathways involved in either AEA or 2-AG formation or in their inactivation, but none of their members do electively activate CB1/CB2 receptors (Di Marzo et al., 1994; Bisogno et al., 2003; Bisogno and Maccarrone, 2014). In the NAEs family there are several bioactive lipids such as the N-oleoylethanolamine (OEA, C18:1) and the N-palmitoylethanolamine (PEA, C16:0), which are produced from oleic acid (OA) or palmitic acid (PA), respectively (Schmid, 2000), as well as the N-linoleoylethanolamine (LEA, C18:2) and the N-stearoylethanolamide (SEA, C18:0) (Ezzili et al., 2010).

On the other hand, in the 2-AcGs family are included lipid congeners with fatty acids of different length such as 2-oleoylglycerol (2-OG), 2-linoleoylglycerol (2-LG) and 2-palmititylglycerol (2-PG) (Murataeva et al., 2016). More abundant in most animal tissues than AEA (Tsboi et al., 2018), the other NAEs show different physiological actions by targeting multiple non-eCB receptors. PEA is a lipid signaling molecule exerting a well described anti-inflammatory, analgesic and neuroprotective activities (Lambert et al., 2012; Mattace Raso et al., 2014), whose effects are in part mediated by the activation of the nuclear peroxisome proliferator-activated receptor-α (PPAR-α) (LoVerme et al., 2005) as well as by the potentiation of AEA action (i.e., the “entourage effect”) at the transient receptor potential vanilloid type-1 (TRPV1) channels (De Petrocellis et al., 2001), or else via the contribution of PPAR-γ and PPAR-δ isoforms (Costa et al., 2008; Paterniti et al., 2013). OEA is an anorexigenic, neuroprotective and lipolytic satiety factor (Rodríguez de Fonseca et al., 2001; Guzmán et al., 2004; Provenzi et al., 2014) that achieves these effects via the activation of PPAR-α receptors. Although with a lesser affinity than PEA, also OEA has been reported to possess agonistic activity at the TRPV1 channels, thus increasing TRPV1-evoked currents (Ahern, 2003; Wang et al., 2005). Moreover, both PEA and OEA, as well as LEA, are able to bind the lipid-activated receptor of the enteroendocrine cells GPR 119 (Overton et al., 2006; Hansen et al., 2011). This ability may be of key importance for the GPR119-mediated intestinal secretion of the incretin hormone glucagon-like peptide-1 (GLP-1), and therefore for the maintenance of insulin secretion/sensitivity and appetite suppression not only in metabolic pathology such as diabetes and obesity but also in neurodegenerative disorders (Brown et al., 2018; Müller et al., 2019).

1.2 Gut Microbial Composition and eCB Signaling: The Powerful Role of Dietary Fat Composition

It is widely recognized that the large gut microbial population, generally named microbiota, is composed of about 100 trillions of microorganisms mainly including anaerobic bacteria, fungi and
protozoa (Ley et al., 2006; Matijašić et al., 2020). Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria are the most copious and representative bacterial species, living in symbiotic “harmony” with the host and significantly contributing to its metabolic and immune functions as well as to the preservation of integrity of the intestinal epithelium (Burcelin, 2016). Such diversity and sensitive symbiotic ecosystem can be selectively perturbed by different lifestyles and nutritional challenges. The two main abundant phyla Firmicutes and Bacteroidetes are also the most susceptible to the shaping action of low- vs. high-fat diet, high-sugar diet and ingestion of different fatty acids, as showed by the incidence of dysbiosis and the higher representation of Firmicutes phyla (e.g., Lactobacillaceae, Veillonellaceae, and Lachnospiraceae) in obesity (Crovesy et al., 2020).

Since eCBs and NAAs are bioactive lipids, their cell and tissue availability can be directly changed by dietary habits and, in particular, by dietary fatty acids composition (Chianese et al., 2017). Indeed, while the n-6 carbon essential fatty acid linoleic acid (LA, 18:2, n-6) is the precursor for ARA biosynthesis (and then for AEA and 2-AG production), the n-3 carbon essential fatty acid α-linolenic acid (ALA, 18:3, n-3) is the precursor of the main n-3 PUFAs docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) from which active metabolites such as N-docosahexaenoyl-ethanolamine (DHEA) and N-eicosapentaenoyl-ethanolamine (EPEA) are also produced (Berger et al., 2001; Maccarrone et al., 2010a). It is well-established that the n-6/n-3 ratio has been dramatically altered by the worldwide adoption of the Western diet (WD) lifestyle especially in the last 50 years, shifting from about 5:1 to the currently estimated 20:1 ratio (Simopoulos, 2006; Blasbalg et al., 2011). A general scheme of the gut-brain interface, including the major pathways of communication involved, the key components of the eCB system and the influence of dietary factors is showed in Figure 1.

Increasing the intake of LA might alter the eCBs levels (Berger et al., 2001; Alvheim et al., 2013; Alvheim et al., 2014), and CB1 receptor function in selected brain areas (prefrontal cortex and nucleus accumbens) can be permanently altered by feeding animals with a n-3 deficient diet during gestation and lactation (Lafourcade et al., 2011). Moreover, there is evidence that the beneficial impact on cognition, or the attenuation of cognitive decline provided by the decrease of dietary n-6/n-3 ratio via n-3 PUFAs dietary supplementation can be preserved both during adolescence and adulthood (Muldoon et al., 2010; Luchtman and Song, 2013), although negative results have also been reported (Stough et al., 2012). The anti-neuroinflammatory and anti-depressive potential of DHA and EPA has been studied in the recent literature in both animal models (Minogue et al., 2007; Moranis et al., 2012) and clinical reports (Rees et al., 2006; Liao et al., 2019), along with their use in dietary supplementation as nutritional guideline to slow down age-associated cognitive decline through preservation of neurogenesis and synaptic plasticity (Dyall, 2015). The levels of dietary LA can affect brain content of 2-AG and AEA and increase liability to obesity (Massiera et al., 2010; Alvheim et al., 2012) but, on the other hand, the different composition of dietary fatty acids can be exploited as anti-obesity agent by both reduction of 2-AG levels (Banni et al., 2011) and the modulation of NAAs concentrations (Pu et al., 2016). Most importantly, the composition of dietary n-3 and n-6 PUFAs and therefore ALA or LA is able to shape the huge microbial community composing the gut microbiota (Marrone and Coccurello, 2019; Wolters et al., 2019). Gut dysbiosis, low-grade inflammation and gut permeability are indeed leading causes for obesity development (Levy et al., 2017; Sun et al., 2018). In obesity, the systemic elevation of the eCB tone (brain included) as well as the upregulation of the CB1 receptor in adipose tissue, liver and muscle have been extensively demonstrated (Matias and Di Marzo, 2006; Starovicz et al., 2008; Silvestri and Di Marzo, 2013). Accordingly, blockade of CB1 receptors may revert both systemic inflammation and dysbiosis induced in obese mice by chronic high-fat diet (HFD) regimen (Mehrpouya-Bahrami et al., 2017).

In support of the idea of a mutual interconnection between endocannabinoids and microbiota, especially in the regulation of energy metabolism (Cani et al., 2016), it has been pointed out that human microbiota can encode N-acyl amides (i.e., eCBs congeners) that can bind G-protein-coupled receptors (GPCRs), thus modulating the intestinal function by the way of the GPR119 (Cohen et al., 2017). Dietary habits and composition are the most important modifiers of the intestinal microbial community (Rinninella et al., 2019), and the eCB machinery is high susceptible to changes in food composition and dietary patterns (Bisogno and Maccarrone, 2014; Passani and Coccurello, 2016; Chianese et al., 2017). In turn, food-induced changes in the eCB system can be paralleled by changes in gut microbiota composition. Switching for only 3 days to a high-fat/high-sucrose diet can produce in the small intestine an increase of AEA and 2-AG together with changes in the abundance of selected bacteria that were found to correlate to blood levels of eCB mediators such as AEA and DHEA (Lacroix et al., 2019). Both eCBs and NAAs plasma levels are directly modulated by nutrients and diet composition, as demonstrated by the switch to a Mediterranean dietary regimen in obese or overweight subjects (Tagliamonte et al., 2021) that reduced AEA levels while increased OEA/PEA and OEA/AEA ratios. Interestingly, the shift from Western-to-Mediterranean diet also produced an increase of faecal content of the mucin-degrading Gram-negative bacterium of the phylum Verrucomicrobia Akkermansia muciniphila (A. muciniphila), whose abundance appears inversely associated with gut dysbiosis and gut permeability (Lopetuso et al., 2020) and therefore is associated to healthy microbial ecology. As “gatekeeper” of intestinal mucosa and gut health, the abundance of A. muciniphila can be modulated by diet and nutrients as demonstrated by fructo-oligosaccharides prebiotic supplementation (Everard et al., 2013). However, not only the fluctuations in A. muciniphila gut abundance are paradigmatic of the tight relationship between diet, gut microbial ecology and (as afterwards discussed) eCB-like lipid mediators (Depommier et al., 2021), but also of the alterations found in gut microbiota of subjects with autism spectrum disorder (ASD). The direct, as well as indirect, impact of macronutrients (mostly fats) on the eCB system of the gastrointestinal (GI) tract and gut-brain signaling have been recently and comprehensively analyzed, especially for the
implication in metabolic disease (Di Patrizio, 2021). In metabolic disease, but also in other clinical conditions, there is evidence that the alteration of selected microbial populations and the administration of eCB or eCB-like lipids may help to rebalance gut bacterial composition. As for instance, vitamin D deficiency was shown to exacerbate neuropathic pain, reducing both gut microbial diversity and 2-AG colon levels, while the supplementation of vitamin D and PEA was shown to attenuate allodynia and rebalance the Firmicutes/Bacteroidetes ratio, including the increase of gut Akkermansia species (Guida et al., 2020).

In this context, a novel route for a future investigation of the relationship between ASD, microbiota and eCB system might also be identified in the analysis of the eating problems/disorders reported in ASD subjects. Indeed, unhealthy eating habits are observed in subjects with ASD in which the incidence of eating disorders (EDs) is much greater than in the general population (Sharp et al., 2013). The higher incidence of EDs and alterations of eating behavior and food selection in ASD patients (Råstam et al., 2013; Sharp et al., 2013; Nickel et al., 2019), suggest to investigate whether in addition to cognitive endophenotypes (Zucker et al., 2007) there might be common gut microbial signatures in EDs and autism along with parallel changes in eCB signaling. A surprising variety of different eating-associated abnormalities afflict children and adolescents who have received a diagnosis of autism. The eating and feeding disorders described span from the more “canonical” EDs (i.e., AN, BN, and BED) to rumination disorder, picky eating, avoidant/restrictive food disorder (ARFID) as well as Pica (i.e., insistent eating of non-food substances) (American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 2012; American Psychiatric Association, 2013; Fields et al., 2021; Inoue et al., 2021). For this reason, these aspects are suggested but not further developed in the present work, hoping that other studies will address in the next future the fascinating issue of multiple dietary approach in ASD (e.g., gluten-free diet or ketogenic diet) will address in the next future the fascinating issue of multiple dietary approach in ASD (e.g., gluten-free diet or ketogenic diet) and parallel impact on eCB system/gut microbiota interplay.

2 eCBs-Microbiota Reciprocal Contamination: Implications for Autism Spectrum Disorder Pathophysiology

Up to now, a limited, but significant number of studies, has provided evidence that mood disorders can be associated with marked changes of eCB signaling that can be mechanistically linked to depressive-like behaviors and alterations of microbiota environment. Although the relationship between gut dysbiosis and NPDs is increasingly documented (Fond et al., 2015; Cenit et al., 2017; Marrone and Coccurello, 2019), evidence for the involvement of eCB-microbiota axis in mood and neurodevelopmental disorders (NDDs) are much more limited. By contrast, recent studies have add evidence in support of the idea that alteration of the eCB signaling system can explain that is possible to use fecal microbiota transplantation (FMT) to transfer depression-like symptoms from “donors” to recipient mice (Chevalier et al., 2020). In particular, this study shows that mice receiving FMT from chronically-stressed mice develop similar depression-like symptoms and concomitant deficits in AA availability, 2-AG synthesis, hippocampal eCB signaling and adult neurogenesis, and that all these effects can be counteracted
by supplementation of probiotic Lactobacillus (i.e., L. plantarum Lp\textsuperscript{WFL}) (Chevalier et al., 2020). In agreement, there is also the elegant demonstration that antibiotic-induced derangement of microbiota composition and alterations of specific members of the eCB system are accompanied by depressive-like behaviors including deficits of social behavior, neuroinflammation and changes of neuronal-glial-microglia communication in the hippocampus (Guida et al., 2018). This study shows that antibiotic exposure increases Proteobacteria and Actinobacteria, while probiotic treatment with Lactobacillus casei DG increases Lachnospiraceae and reduces Enterococcaceae and Bacillaceae, thus mitigating the morphological alterations observed in hippocampal astrocytes and microglia. Notably, antibiotic-induced dysbiosis was associated with a marked reduction in the small intestine of two eCBs members, one of them (i.e., N-arachidonoylserotonin (AA-5-HT) involved in the inhibition of FAAH and the TRPV1 channel as well as in antidepressant activity (Navarra et al., 2014), which resulted normalized by probiotic treatment (Guida et al., 2018). The major alterations of eCBs and eCB-like lipid mediators in the brain widely reported in germ free (GF) mice (Manca et al., 2020b), further corroborate the idea that the eCB signaling system mediates many functions of the bidirectional microbiota-gut-brain communication. Even beyond the implications for NDDs, there is now evidence that the complex homeostatic role exerted by the eCB system and eCB-like mediators is including unpredicted functions such as those recently described for the intestinal expression of the liver-expressed antimicrobial peptide 2 (LEAP2), which is partially regulated by eCB system-microbiota interaction and is important for the impact of nutrients on energy metabolism (Shen et al., 2022).

ASD is one of the most challenging, disabling and heterogeneous NDD, characterized by the impairment in social communication and social interaction, limited interests, repetitive and stereotyped patterns of behaviors (American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 2012). The significant association between abnormal changes in gut microbiota, GI disorders and ASD symptoms provides the strong rationale to consider the severe alteration of the microbial gut community of ASD subjects as an important pathogenetic factor in ASD development. The number of evidence supporting the concept of gut dysbiosis in ASD is constantly growing, as for instance by the demonstration that GM mice receiving microbiota samples from ASD human donors develop ASD-like symptoms (Sharon et al., 2019). Before introducing the impact of the eCBs complexity in the brain-gut microbiota axis/ASD pathophysiology, we suggest to refer to Figure 2 that provides a schematic idea of the different environmental challenges and multiple threats responsible of gut dysbiosis and increasing risk of ASD during the neurodevelopment. Under prenatal and postnatal burden, abnormal gut function and dysbiosis may become a prevalent inflammatory condition leading to an alteration of brain-gut axis signaling. As consequence, the loss of intestinal integrity and leaky gut causes detrimental bacterial components transfer to circulation, increasing risk and susceptibility to ASD. The eCB system establishes a tight functional interaction with the gut microbiota ecosystem and participate to the regulation of neuroepithelial gut barrier physiology contributing to determine intestinal permeability via CB\textsubscript{1} receptor activation within the intestinal epithelium and/or enhancement of AEA/2-AG signaling (Karwad et al., 2017). Accordingly, blockade of CB\textsubscript{1} receptors attenuates inflammation in gut microbiota and diet-induced obesity intestinal permeability (Mehrpooya-Bahrami et al., 2017). Indeed, GM mice show severe alterations of intestinal eCBs gene expression and consequent changes of eCB signaling (Manca et al., 2020a).

Thus, the eCBs-microbiota partnership could have a distinctive role in the ASD, both for the understanding of its complex pathogenesis as well as in relation to the discovery of novel therapeutics. In this context, the mutual communication between the microbiota ecosystem and eCB signaling appears represented by the ASD, in which microbiota dysfunction and changes in the eCB system have been described either in association or as independent “causal” factors. The so-called “recreational” use of Cannabis sativa and, consequently, the empirical experience that its consumption in a variety of different forms (e.g., fiber hemp, seeds and female flowers) and modalities (e.g., ingestion, inhalation and smoking) dramatically affect human social behavior is known from thousands of years (Ren et al., 2019). Although social behavior is generally self-assessed by Cannabis users, the most part of subjective feelings reported converge towards the description of pro-social behaviors enhancement, including more social interactions, less agonistic actions and hostility, a greater involvement in social play, higher sociability such as empathy and altruism, and less social anxiety (Wei et al., 2017). Nevertheless, Cannabis chronic consumption/intake is also associated with important psychoactive effects provoking major concerns in clinicians, especially at the light of the significant (though not yet prevalent) and growing consensus around the medical use of Cannabis (Hall et al., 2019). As recognized, the adverse effects on mood, anxiety and cognition are almost exclusively imputable to the main psychoactive component of the Cannabis Δ\textsubscript{9}-tetrahydrocannabinol (THC) (Dow-Edwards and Silva, 2017), which makes impossible the mere hypothesis of Cannabis’s use for medical purpose, and particularly in the case of developing brains, as for all NDDs. Among the over hundred phytocannabinoids present in the Cannabis plant, cannabidiol (CBD) has attracted a great interest for the lack of psychoactive effects provoking major concerns in clinicians, especially at the light of the significant (though not yet prevalent) and growing consensus around the medical use of Cannabis (Niesink and van Laar, 2013). Indeed, CBD is a non-cannabinimimetic component that does not bind (i.e., has a very low affinity) CB\textsubscript{1} and CB\textsubscript{2} receptors, while it exerts inverse agonism at CB\textsubscript{2} receptors (Thomas et al., 2007) and negative allosteric modulatory activity at CB\textsubscript{1} receptors (Laprairie et al., 2015). Additional pharmacological features describe the CBD as a chemical compound able to inhibit, via FAAH, AEA hydrolysis and produce antipsychotic effects (Leweke et al., 2012), and a phytocannabinoid with agonistic activity at 5-HT\textsubscript{1A} receptor (Russo et al., 2005) and desensitization activity of TRPV1 (Bisogno et al., 2001), thus providing anti-inflammatory,
analgesic, anti-depressant and anxiolytic effects (Schier et al., 2014; Shannon et al., 2019; Atalay et al., 2020). Interestingly, CBD also binds the orphan G protein-coupled receptor 55 (GPR55), a recently included new member of the eCB family (Sharir and Abood, 2010), showing an involvement in several mechanisms accountable for the exacerbation of inflammatory processes (Yang et al., 2016). GPR55 is densely distributed all along the GI tract where its expression increase in case of intestinal inflammation, which can be relieved by its pharmacological blockade (Stanoić et al., 2015). Of note, a partial antagonistic activity has been described for CBD at the GPR55 (Ryberg et al., 2007), thus disclosing one of the mechanisms through which CBD can achieve its anti-inflammatory effects.

2.1 eCB Signaling in ASD

Evidence is growing that many aberrant behaviors (in the sphere of emotionality, cognition and social disabilities) comprised in psychiatric NDDs, such as schizophrenia and ASD, can be improved by modifying the eCB signaling (Muguruza et al., 2013; Zamberletti et al., 2017). Indeed, there is a significant comorbidity between anxiety and ASD (van Steensel et al., 2011), and reduced serum levels of AEA, PEA and OEA has been found in children with ASD (Aran et al., 2019). The strong involvement of eCB signaling in the behavioral expression of deficits in social interaction has been elegantly demonstrated in the Srč homology domain 3 and multiple ankyrin repeat domains 3 (SHANK3) mouse model of ASD-like behavior (Folkes et al., 2020). The model (i.e., Shank3B−/−) has been developed on the ground of the mutations and variants in SHANK3 encoding genes that have been found in patients with ASD (Vorstman et al., 2006; Boccuto et al., 2013; Kazdoba et al., 2016), which recapitulate loss of function of SHANK3 protein and ASD-like deficits in social behavior. The authors disclosed the role played by the basolateral amygdala-nucleus accumbens (BLA-NAc) circuit in the impairment of social behavior and elicitation of social avoidance, and demonstrated that an increase of social behavior was similarly achieved either by the inhibition of this BLA-NAc circuit in the Shank3B−/− mouse, or by the increase of eCB signaling in both wild-type mice and ASD-like Shank3B−/− mouse (Folkes et al., 2020). In particular, the increase in sociability was obtained by administering a selective MAGL inhibitor, thus demonstrating not only the involvement of eCB signaling in ASD pathogenesis but also the specific action produced by the increase of 2-AG mediated signaling. Even more recently, the same Shank3 mutant mouse model has been used to evaluate the efficacy of a CBD-enriched cannabis oil in alleviating repetitive behavior and anxiety (Poleg et al., 2021). Along with a reduction of these ASD-like behaviors, including anxiety, this study evidenced the role of both CB1-mediated transmission and THC underlying the beneficial effect of medical cannabis-based treatment (Poleg et al., 2021). The anxiolytic activity of CBD has been well described in subjects with generalized social anxiety disorder (Crippa et al., 2011). Although not in lack of side effects, the conclusions of some studies completed by using CBD-enriched oil(s) in children with ASD (Pleury-Teixeira et al., 2019; Ponton et al., 2020; Loss et al., 2021) supports both the general improvement of symptoms (e.g., hyperactivity, anxiety, social abilities) and the idea of feasibility of CBD- and phytocannabinoid-based treatment for ASD. Similar conclusions have been outlined in an observational study reporting about 30% and 50% of significant and moderate symptoms improvement, respectively (Bar-Lev Schleider et al., 2019).

2.2 eCB Signaling, ASD and Gut Microbial Diversity: The Oxytocin Link

Considering the key involvement of eCB signaling in social bonding and sociality (Rapino et al., 2011) and the possibility to attenuate social phobia and social anxiety by increasing the eCB tone (Trezza et al., 2012; Micale et al., 2013), it was found that serum levels of AEA, PEA and OEA have been found decreased in subjects with ASD (Aran et al., 2019). In parallel, because of the involvement of the neuropeptide oxytocin in social cognition, social memories and facial recognition (Logatina et al., 2018; Froemke and Young, 2021), there are studies in which oxytocin administration in patients with ASD has demonstrated either to improve some symptoms (e.g., emotion recognition, orientation towards human sounds) (Guastella et al., 2010; Lin et al., 2014) or to fail in eliciting significant differences between oxytocin-treated subjects and placebo group (Sikich et al., 2021). The eCB system functionally interact with the oxytocinergic transmission, which is known to exert anxiolytic effects and improve affiliation and social behavior (Yoon and Kim, 2020; Froemke and Young, 2021). Indeed, some central effects mediated by eCB congeners such as OEA have been demonstrated to depend on oxytocin signaling (Provensi et al., 2014), and several effects induced by the potentiation of oxytocin signaling such as reward-associated social interaction can be attenuated or suppressed by the antagonism at CB1 receptors (Wei et al., 2015). If AEA or OEA are directly involved in oxytocin-driven social reward (Wei et al., 2015), feeding (Provensi et al., 2014) and oxytocin secretion (Romano et al., 2013), there are then solid reasons to believe that, at least part of the pro-social effects obtained through oxytocin administration, could be attributed to eCB signaling. In this respect, it is worth quoting a recent functional magnetic resonance imaging study in which was observed a significant bilateral reduction of amygdala activity after subchronic intranasal oxytocin delivery, in positive correlation with symptoms relief, so that the lower the amygdala activity the greater the behavioral improvement (Bernaerts et al., 2020). Although the study by Folkes et al. (2020) did not discuss the results at the light of other connections, circuits, and functional interplay between different signaling systems, it is suggestive that the inhibition of the BLA-NAc circuit in the Shank3B−/− ASD-like mouse model led to an improvement of social behavior and social avoidance. Moreover, the fact that sociability was boosted in this study via an increase of 2-AG signaling further strengthens the idea that the potential therapeutic provided by oxytocin delivery could be ascribed to the potentiation of eCB signaling.

The higher incidence of GI dysfunctions (e.g., abdominal pain, diarrhea but also constipation, food allergies and gluten-
associated disorders) in children with autism than in control population is well documented (Ashwood et al., 2012; Xu et al., 2018), together with the interesting association between GI abnormalities, and severity of core symptoms such as more severe social withdrawal and anxiety in ASD (Hsiao, 2014). Moreover, as mentioned, microbiota dysfunction in terms of changes of gut bacterial composition, alteration of the integrity of the epithelial gut surface and abnormal intestinal permeability (“leaky gut”) are all recurrent clinical features in ASD population (Ristori et al., 2019). From this view, the CB2 receptor-mediated signaling may be an interesting player to connect eCB signaling, neuromodulatory activity of inflammatory processes, and ASD pathogenesis.

Thus, by focusing on the characterization of dysbiosis in autistic children is also possible to uncover the existence of correlations with altered oxytocin plasma levels in these patients and, indirectly, to reveal the existence of additional correlations linking the growth of pathogenic bacterial genera to the eCB system. By comparing gut microbiota of healthy controls and ASD subjects, a recent study has disclosed the existence of lower oxytocin plasma levels in ASD as well as an inverse correlation between oxytocin levels and increased abundance of genera bearing to the Clostridiales family (Huang et al., 2021). Among the bacterial genera present in higher abundance in the gut of ASD children, it was described an increase of Erysipelotrichaceae family, a butyrate-producing bacteria found abnormally grew in these patients (Huang et al., 2021). Interestingly, the only two bacterial families found reduced in gut microbiota of MAGL KO mice (Mgll−/−) were Lactobacillaceae and Erysipelotrichaceae (Dione et al., 2020), thus in animals showing increased levels of 2-AG and 2-AG congener 2-monoacyl-glycerols (i.e., 2-MAGs) (Dione et al., 2020). In other terms, in biological systems where both 2-AG and 2-MAGs are elevated due to selective deletion of their hydrolzing enzyme (i.e., MAGL) is possible to observe a decrease of some bacterial families that, by contrast, are elevated in ASD children with lower oxytocin plasma levels.

As mentioned, in addition to butyrate-producing bacteria, in subjects with ASD is frequently observed an increase of propionate-producing bacteria such as clostridia and Desulfovibrio bacteria (Finegold et al., 2010; De Angelis et al., 2013; de Angelis et al., 2015) that, when excessive, may induce neurotoxicity and neurotransmitter dysbiosis (Al-Salem et al., 2016). Accordingly, a diagnosis of autism is more frequent in subjects with propionic acidemia (Witters et al., 2016), and the experimental delivery (e.g., intracerebroventricular) of propionate has demonstrated to reproduce in rodents an entire set of ASD-like behaviors (Shultz et al., 2009; Meeking et al., 2020). Interestingly, CB2 receptor blockade can induce marked changes in the gut microbial community such as an increase of propionate production (Mehrpouya-Bahrami et al., 2017), and a downregulation of CB2 receptors has been disclosed in the post-mortem examination of brains of subjects with autism (Purcell et al., 2001). Hence, the overrepresentation in the gut community of ASD subjects of propionate-producing bacteria may contribute to the expression of ASD symptoms, and the downregulation of CB2 receptors contribute to propionate production and ASD pathophysiology.

### 2.3 ASD and the eCB Signaling-Gut Microbiota Reciprocal Influence

If ASD is a NDD accompanied by comorbid GI disorders and intestine inflammation, then we also know that eCBs and diet are reciprocally and metabolically linked and that the eCB system may be modulated not only by dietary factors and lifestyles (Bisogno and Maccarrone, 2014; Passani and Coccurello, 2016; Coccurello and Maccarrone, 2018), but also by gut microorganisms and selected bacterial taxa that can change circulating eCBs and regulate immune function and adaptive immunity (Castonguay-Paradis et al., 2020; Zheng et al., 2020). The eCB system is widely distributed all along the GI tract (Izzo et al., 2015) and the eCBs of the intestinal epithelium are functionally involved in the control of gut-brain signaling, thus influencing and being influenced by gut microbiota composition.

An elegant demonstration of this reciprocal influence is for instance showed via the association between anhedonia, as key diagnostic symptom in depression (Coccurello, 2019), and gut microbiota composition both in an animal model of depression-like behavior (Chevalier et al., 2020) and in a population cohort of volunteer twins (Minichino et al., 2021). The authors of this latter study used a model of analysis and a working hypothesis through which microbiota diversity can be exploited to predict changes in faecal and/or serum levels of eCBs and occurrence of anhedonia as trait of personality in the general population (Minichino et al., 2021). Notably, they found that PEA faecal (but not serum) levels mediates such association between microbial diversity and anhedonia incidence, further supporting the critical importance of the endocannabinoids-microbiota partnership for the understanding of symptoms that may anticipate the onset of a large set of neuropsychiatric and NDDs, including depression, substance abuse and ASD (Marrone and Coccurello, 2019). Paradigmatic is the case of A. muciniphila, a mucin-degrading Gram-negative bacterium able to regulate tight junctions and preserve gut health, whose activity opposes different pathogenetic mechanisms underlying metabolic diseases among which gut permeability, and for this also baptized “gut gatekeeper” (de Vos, 2017; Chelakkot et al., 2018). Indeed, A. muciniphila supplementation was shown to improve gut permeability, previously degraded by obesity-associated inflammation, and produce an increase of 2-AG intestinal levels (Everard et al., 2013). Later, the A. muciniphila beneficial effects have been attributed to a couple of eCB-derived lipids of the 2-AcGs family (i.e., 1-Palmitoyl-glycerol (1-PG) and 2-PG), and to their ability to bind the PPARα receptor (Depommier et al., 2021). Studies exploring changes of A. muciniphila density in the gut of ASD children have reported conflicting results. A. muciniphila abundance was found decreased according to the results by Wang et al. (2011), while was reported increased in another investigation (De Angelis et al., 2013). Nevertheless, here the main point is that important changes in the abundance of a bacterium that utilizes colonic
mucin as substrate and protect from gut inflammation are frequently described in ASD, and that alterations of *A. muciniphila* can be mirrored by changes of eCB signaling.

Besides several studies reporting the beneficial effects of PEA supplementation on neurodegeneration (e.g., hippocampal damage) and social and non-social behaviors in different ASD-like rats and mice models (Bertolino et al., 2017; Cristiano et al., 2018; Herrera et al., 2018), an improvement of language skills following PEA supplementation has also been reported in two children with autism (Antonucci et al., 2015). Interestingly, PEA treatment in the ASD-like BTBR mouse model (Cristiano et al., 2018) also reduced pro-inflammatory cytokine production and intestinal permeability (“leaky” gut) at intestinal/colonic level. The PEA potential against clinical conditions involving GI inflammatory disorders has been shown in different models, as for experimental colitis in which the positive impact on inflammation and intestinal permeability has been attributed to the mediation of GPR55, PPAR-α, and CB2 receptors (Borrelli et al., 2015). Among the interesting animal models of autistic-like behaviors (e.g., *fmr1* knockout) there is the exploitation of fragile X syndrome (FXS) and ASD comorbidity (Abbeduto et al., 2014) through the expansions mutations of *FMR1* gene, which greatly increase the incidence of ASD disabilities (Bailey et al., 2008). The seminal investigation of the eCB system in different animal models of FXS (Maccarrone et al., 2010b) has provided evidence that in mice lacking both the *FMR1*-encoding FXS protein FMRP (FMRP KO mice) and the regulatory brain cytoplasmic 1 RNA (BC1 KO mice) there is a severe alteration of the functional coupling between metabolotropic glutamate 5 receptors (mGlustRs) and eCB signaling. Indeed, in double KO mice FMRP-BC1 was observed a marked disinhibition of mGlust5-mediated activity leading to an increased activity of 2-AG-synthesizing enzyme diacylglycerol lipase (DAGL) and enhanced 2-AG levels (Maccarrone et al., 2010b). Of note, striatal levels of 2-AG were not found changed in FMRP KO mice but an increased activity of the enzyme responsible for 2-AG degradation (i.e., MAGL) was instead observed, thus suggesting a decrease of 2-AG tone/signaling in a brain region whose function is considered of key importance for autism pathophysiology (Fuccillo, 2016). Along the same line of thought, FMRP KO mice do not display the correct functional coupling between mGlust5R-dependent long-term depression and mGlust5-DAGL-dependent 2-AG release at the postsynaptic excitatory synapse, and inhibition of glutamate release upon 2-AG stimulation of presynaptic CB1 receptors (Jung et al., 2012). Ultimately, this means that 2-AG production is downscaled, and blockade of 2-AG degradation through MAGL inhibition reinstated eCB-LTD in the striatum and normalized abnormal behavioral disinhibition in the elevated plus maze (Jung et al., 2012). More recently, a couple of studies showed that the increase of AEA signaling via pharmacological FAAH inhibition can counteract either social deficit (Wei et al., 2016) or aversive memory (Qin et al., 2015), not only in FXS animal model (i.e., *fmr1*/FMRP KO mouse), but also induce an improvement of social impairment in the BTBR mouse model of ASD-like behavior (Wei et al., 2016). To further corroborate the functional association between ASD and eCB signaling, and in line with the dysregulation of 2-AG metabolism found in different animal models of FXS (Maccarrone et al., 2010a; Jung et al., 2012), also the use of neurodevelopmental models of autism such as the prenatal exposure to valproic acid (VPA) has provided evidence for reduced DAGL-α activity in the cerebellum and concomitant increase of MAGL-dependent 2-AG degradation in the hippocampus (Kerr et al., 2013). The same study also shown that social exposure was able to induce an enhancement of hippocampal levels of NAes such as PEA and OEA (Kerr et al., 2013). This study appears to match the framework emerging from the analysis of gut microbiota dysbiosis in depression-like behaviors in which has been described a reduced synthesis of 2-AG (Chevalier et al., 2020), as well as the aforementioned increase of 2-AG intestinal levels induced by *A. muciniphila* supplementation (Everard et al., 2013) and, although not always reported, the decrease of *A. muciniphila* abundance in children with autism (Wang et al., 2011). A brain decrease of NAPE-PLD expression and a parallel increase of FAAH-dependent AEA degradation following exposure to VPA prompts for the idea that defective AEA metabolism could, at least in part, account for the ASD-like deficits in social communication induced by VPA exposure (Servadio et al., 2016). Incidentally, the reduction of 2-AG (Kerr et al., 2013) and particularly of AEA (Servadio et al., 2016) brain levels described after exposure to VPA is reminiscent of the decrease of AEA serum levels observed in children with ASD (Aran et al., 2019), while pharmacological FAAH inhibition was shown to mitigate VPA-induced deficits in social behavior (Kerr et al., 2016).

Although with a significant variability of the bacterial taxa involved, gut microbial diversity is severely disrupted in ASD children. Overall, a reduced ratio of Bacteroidetes to Firmicutes in ASD patients is more frequently portrayed (De Angelis et al., 2013; Strati et al., 2017), as well as the fact that *Clostridium* and *Desulfovibrio* are generally found as pathologically dominant species (Finegold et al., 2010; de Angelis et al., 2015). By contrast, beneficial bacteria such as *Bifidobacterium* are commonly underrepresented in the altered bacterial profile of children with ASD (Adams et al., 2011; de Angelis et al., 2015).

Interestingly, changes in gut microbiota dysregulates the intestinal eCB system, and probiotic supplementation with *Lactobacillus acidophilus* induced an increase of CB2 receptor mRNA expression in mice colon (Rousseaux et al., 2007), which may be of importance for the above mentioned data concerning the upregulation of CB2 receptors in PBMCs of autistic patients (Siniscalco et al., 2013). The use of different *Lactobacillus* strains, in both experimental models of ASD-like behavior and clinical trials conducted on children with ASD, has provided increasing evidence that selected probiotics can ameliorate ASD symptoms. Here, it is worth remember the improvement of social deficits and the recovery of oxytocin levels in the paraventricular nucleus (PVN) of the hypothalamus obtained in offspring from obese mothers through the selective administration of *Lactobacillus reuteri* (Buffington et al., 2016). As noted, the alterations of the gut microbiota ecosystem in ASD patients include marked deficiencies in some bacterial species, such as *Bifidobacterium* species, which can be regulated by a class of probiotics/
“psychobiotics” (Dinan et al., 2013) able to shape the diversity of commensal gut bacteria and affect several CNS functions and psychiatric diseases through different gut-to-brain routes of communication (e.g., enteric nervous system, vagal signaling, bacteria-derived metabolites and microbiota-neuroimmune axis) (Sarkar et al., 2016). The oral treatment with Bacteroides fragilis in offspring from mothers underwent immune activation improves both integrity of epithelial barrier and social-communicative deficits, restoring physiological gut composition and serum metabolites (Hsiao et al., 2013). Some of these Bifidobacterium species that are modulated by probiotic administration have been found strongly reduced in ASD pathophysiology, as demonstrated for the significant depletion of Bifidobacterium longum (B. longum) in young children with ASD (Coretti et al., 2018). Interestingly, the shift from Western diet to the consumption of Mediterranean diet was found to increase plasma OEA/PEA ratio, and such increase was observed to positively correlate with the growth of several microorganisms, included B. longum (Tagliamonte et al., 2021). Moreover, the administration of B. longum (under the form of probiotic mix) was shown to increase in zebrafish the intestinal mRNA expression of Cnr1 and Cnr2 genes thus providing molecular evidence of the contribution of eCB signaling, and in particular of the involvement of CB2 receptor-mediated signaling, in the anti-inflammatory effects achieved by probiotics administration (Gioacchini et al., 2017). Among other living bacteria and in addition to B. longum, the probiotic mix used included the Lactobacillus acidophilus and the Bifidobacterium infantis, and the study also showed a significant decrease of faah and mgll gene expression, thus suggesting a reduced degrading activity for both the enzymes and the potential increase of AEA- and 2-AG-mediated signaling (Gioacchini et al., 2017).

Bifidobacterium species in general, and B. longum in particular, recruit multiple pathways and mechanisms to provide their well-known health benefit in humans (e.g., in a variety of GI disorders). Indeed, the impact of B. longum on intestinal ecology is triggered via different mechanisms among which the stimulation of the activity of butyrate-producing bacteria via acetate production (Sugahara et al., 2015). Butyrate (or butyric acid) is a short chain fatty acid (SCFA) that, likewise other SCFAs (e.g., acetate and propionate), is produced by the gut microbiota upon fermentation of non-digestible carbohydrates (Morrison and Preston, 2016). By exploiting its features of histone deacetylases (HDAC) inhibitor, butyrate treatment has been used in ASD-like mice models such as in the prenatal exposure to VPA (Takuma et al., 2014) and in the BTBR model of autism (Kratsman et al., 2016), in both cases describing improvements either in recognition memory or in social behavior. However, data incoming from ASD population are more controversial. On one hand, there are data collected in Chinese ASD patients in which are described lower than normal levels of faecal butyrate and reduced abundance of butyrate-producing bacteria (e.g., Lachnospiraceae) (Liu et al., 2019). On the other hand, there are data analysis in which a drastic reduction in B. longum microbiota colonization is reported together with an increase of the butyrate-producing bacterium Faecalibacterium prausnitzii (Coretti et al., 2018). Moreover, the severity of ASD symptoms appears to

![Figure 3](https://example.com/figure3.png)

**FIGURE 3** | The figure portraits selected evidence in support of eCB signaling-gut microbiota relationship and representative mechanisms underlying the link between ASD pathophysiology and the eCB machinery. On the left panel (A), A. muciniphila supplementation can improve gut permeability and recover gut integrity as well as increase 2-AG signaling. Supplementation of Lactobacillus acidophilus increases both 2-AG and AEA signaling and CB2 receptor mRNA expression in mice colon and in human epithelial cells. B. Longum supplementation is associated with increase of Cnr1 and Cnr2 genes intestinal expression. Below, an overall growth in Bacteroides population can produce an increase of eCB-like lipids (e.g., OEA and 2-OG) acting as GPR119 ligands. Recovery of gut microbial balance (e.g., Firmicutes to Bacteroides ratio) can be associated with PEA supplementation and an increase of 2-AG signaling cause an improvement of sociability. On the right panel (B), downregulation of CB1 receptors found in brains of subjects with autism, and decrease of serum AEA, PEA and OEA levels in ASD patients. Below, some evidence of dysregulation of gut microbial community and reduced bacteria diversity. Gut dysbiosis in ASD is characterized by disrupted gut barrier integrity and increased gut permeability as well as by a general Firmicutes to Bacteroides imbalance. Next, the increase of Clostridia and Desulfovibrio bacteria as well as of Erysipelotrichaceae family are responsible of excessive propionate- and butyrate-producing bacteria, respectively. Boosting eCB tone and 2-AG and AEA signaling via prebiotics supplementation emerges as potential therapeutic via changes of gut microbial communities found defective in ASD patients.
inversely correlate to *Faecalibacterium* genus (Ding et al., 2020), and a further confirmation of the increase of butyrate faecal level in children with ASD has been previously reported (Wang et al., 2012). Recently, it has been provided evidence that gut microbial metabolites, and specifically butyrate, can directly modulate the eCB tone at gut epithelial level (Hwang et al., 2021). Using different concentrations, the study showed that both eCBs synthesizing enzymes (i.e., NAPE-PLD and DAGL) were reduced by butyrate treatment in dose-dependent manner, and that in parallel butyrate was able to upregulate MAGL (but not FAAH) expression in the gut epithelial cells (Hwang et al., 2021). Accordingly, it seems conceivable that an excessive increase of butyrate level in children with ASD (Wang et al., 2012; Coretti et al., 2018) could contribute to reduce both AEA and 2-AG synthesis and, in particular, cause a depletion of 2-AG tone in the gut epithelium. Moreover, this point of view appears compatible with the decrease of AEA, PEA and OEA serum levels in children with ASD (Karshon et al., 2018; Aran et al., 2019). A recent investigation has compared the potential derangement of the eCB machinery in children with autism as well as in the ASD-like VPA animal model (Zou et al., 2021). Data from this study account for a general decrease of eCB signaling, which is corroborated by the increased expression of both mRNA and protein levels of CB2 receptors and eCB degrading enzymes FAAH and MAGL in PBMCs from autistic children (Zou et al., 2021). Of particular interest, the study not only confirmed the reduced blood concentration of AEA, PEA and OEA (Kazdoba et al., 2018; Aran et al., 2019) and the upregulation of CB2 receptors at PBMCs level (Siniscalco et al., 2013), but also reported a reduction of 2-AG serum levels in ASD patients (Zou et al., 2021). Here, Figure 3 can provide a snapshot of the reciprocal influence between eCB signaling and gut microbiota in ASD, as well as of the therapeutic potential that results from the boosting of eCB tone through the involvement of the gut microbial community.

Besides the effects of CBD in the Shank3 mouse model of autism (Poleg et al., 2021), and the ASD-like neurophatological phenotype and deficits in social behavior described in models of prenatal exposure to VPA, in BTBR (Kratsman et al., 2016) and in FXS *fmr1* KO mice (Kazdoba et al., 2016), there is another link between mutations in Synapsin (SYN) genes and patients with comorbid ASD and epilepsy that is worth exploring (Passio et al., 2011). Here, the relevance comes from the role that synapsins play in the regulation of synaptic transmission, plasticity, and neural development (Fornasiero et al., 2010). In particular, as demonstrated by the sophisticated assessment of ultrasonic vocalizations, synapsin II KO mice (i.e., Syn2) exhibited more marked deficits in social communication and therefore a substantial ASD-like phenotype (Michetti et al., 2017). Notably, from a functional point of view, synapsins also participate in eCB-induced neural plasticity so that the stimulation of CB1 receptors was shown to modulate the increase of synaptic vesicles by controlling synapsins phosphorylation and downstream activation of synaptic transmission (Patzke et al., 2021). Remarkably, restoration of gut dysbiosis by FMT was shown to normalize the reduced expression of presynaptic synapsin-1 expression in the APP/PS1 mouse model of Alzheimer’s disease (Wang et al., 2021), thus corroborating the use of ASD-like synapsin II KO mice for the study of the relationship between eCB signaling and gut microbiota in ASD development.

A further point worth of consideration, briefly outlined in the introduction, involves the deleterious effects of vitamin D deficiency on the reduction of microbial diversity were briefly mentioned as a convincing example of the eCB-microbiota reciprocal contamination, especially in the light of the beneficial results produced by PEA supplementation on the recovery of a balanced Firmicutes/Bacteroidetes ratio (Guida et al., 2020). Mice bearing a deletion of vitamin D receptor show dysbietic microbial profile with a marked reduction of *A. muciniphila*, thus strengthens the importance of vitamin D signaling for the maintenance of intestinal integrity and eubiosys (Su et al., 2016). However, these examples could not be limited to the detrimental effects induced by vitamin D deficiency on dysbiosis but encompass the study of ASD pathogenesis. Indeed, accumulating evidence are in line with the notion that vitamin D deficiency during pregnancy can increase the risk of NDDs including ASD development (Lee et al., 2021), as well as that vitamin D supplementation might improve the expression of ASD symptoms (Principi and Esposito, 2020). Moreover, vitamin D deficiency during development has been associated to the risk of NPDs such as schizophrenia (McGrath et al., 2010). In support of a functional interplay between eCB signaling and vitamin D metabolism, there are the disruptive effects induced by high-dose systemic Δ9-THC administration in tasks simulating schizophrenia-like aberrant processing that were boosted by developmental vitamin D deficiency (Burne et al., 2014). A recent study addressing on astrocytes specific markers of neuronal aging and the anti-inflammatory potential of PEA (e.g., against reactive oxygen species and nitric oxide production) reported greater neuroprotective effects through the use of an innovative drug formulation consisting in PEA, alpha lipoic acid and vitamin D combination (Morsanuto et al., 2020). Not only the PEA/alpha lipoic acid/vitamin D formulation showed better cell viability, anti-inflammatory and anti-oxidant effects but also higher potency in the inflammatory potential of PEA (e.g., against inflammatory species and nitric oxide production) reported greater neuroprotective effects through the use of an innovative drug formulation consisting in PEA, alpha lipoic acid and vitamin D combination (Morsanuto et al., 2020). Not only the PEA/alpha lipoic acid/vitamin D formulation showed better cell viability, anti-inflammatory and anti-oxidant effects but also higher potency in the inflammatory potential of PEA (e.g., against inflammatory species and nitric oxide production) reported greater neuroprotective effects through the use of an innovative drug formulation consisting in PEA, alpha lipoic acid and vitamin D combination (Morsanuto et al., 2020). Not only the PEA/alpha lipoic acid/vitamin D formulation showed better cell viability, anti-inflammatory and anti-oxidant effects but also higher potency in the inflammatory potential of PEA (e.g., against inflammatory species and nitric oxide production) reported greater neuroprotective effects through the use of an innovative drug formulation consisting in PEA, alpha lipoic acid and vitamin D combination (Morsanuto et al., 2020). Not only the PEA/alpha lipoic acid/vitamin D formulation showed better cell viability, anti-inflammatory and anti-oxidant effects but also higher potency in the inflammatory potential of PEA (e.g., against inflammatory species and nitric oxide production) reported greater neuroprotective effects through the use of an innovative drug formulation consisting in PEA, alpha lipoic acid and vitamin D combination (Morsanuto et al., 2020). Not only the PEA/alpha lipoic acid/vitamin D formulation showed better cell viability, anti-inflammatory and anti-oxidant effects but also higher potency in the inflammatory potential of PEA (e.g., against inflammatory species and nitric oxide production) reported greater neuroprotective effects through the use of an innovative drug formulation consisting in PEA, alpha lipoic acid and vitamin D combination (Morsanuto et al., 2020).
and changes in gut microbiota (Su et al., 2016; Guida et al., 2020; Morsanuto et al., 2020). Several key studies discussed in subchapters from Section 2.1 to Section 2.3 are summarized in Table 1.

3 ENDOCANNABINOIDS-MICROBIOTA RECIPROCAL CONTAMINATION: ASD, NEUROINFLAMMATION AND IMMUNE DYSFUNCTION

In spite of the quite elusive ASD etiology (Strathearn, 2009; Gwyali and Patra, 2019), there is a parallel field of investigation that started to look at some mechanisms of brain inflammation that may help to better understand this highly disabling NDD. In the search of pathogenetic mechanisms underlying ASD, it is not a mystery that the dysfunction of immune system is more than an ordinary hypothesis (Onore et al., 2012), which even include the possibility to consider ASD as an autoimmune disease (Hughes et al., 2018). If, as resident macrophages, microglia are the main innate immune cells of the brain (Hanisch and Kettenmann, 2007) and the eCB system is one of the major driver of the surveillance activity implemented by microglial cells (Mecha et al., 2015), then changes of eCB signaling can be responsible not only of healing and reparative processes but also of ASD pathogenesis. Aberrant changes in microglial cells morphology have been detected in postmortem brain of ASD subjects, and in particular a significant decrease in ramified microglia together with an increase in primed microglia in the gray matter of temporal cortex, thus supporting the idea that ASD is characterized by selective changes in microglial phenotypes (Lee et al., 2017). In a recent survey of the postmortem studies completed on the brain of subjects with ASD, the morphological alterations of microglia found in these samples were sufficient to account for the presence of neuroinflammation as etiological factor in ASD (Liao et al., 2020). CB2 receptors are mostly present on microglia and the relative level of expression of these receptors changes accordingly with the stage of neuropathology (Stella, 2009; Tanaka et al., 2020), and as function of the ability to regulate phagocytosis and transform the microglia phenotype from M1 to the anti-inflammatory M2 (Mecha et al., 2015). Remarkably, the eCB machinery and the switching between microglia phenotypes bidirectionally modulate each other. Indeed, in the M1 microglia phenotype both eCB receptors are downregulated while CB2 receptors are upregulated in both M2 activated subtypes M2a and M2c that, in turn, have been shown to promote the synthesis of 2-AG and AEA, respectively (Mecha et al., 2015). As evidenced by the actions of immunosuppressive drugs (Hughes et al., 2018), immune dysfunction is a key factor in ASD pathogenesis (Buffington et al., 2016) and CB2 receptors mediate many inflammatory processes and are highly expressed in immune cells (Chiurchia et al., 2015; Turcotte et al., 2016). However, while in non-pathological conditions the expression of CB2 receptor is quite limited in the CNS, its expression is dramatically increased in microglial cells in case of neurodegenerative disorders such as Alzheimer’s disease (Benito et al., 2003; Benito et al., 2008), which is interpreted as a defense mechanism against neuroinflammation. CB2 receptors are particularly expressed in B lymphocytes (Lee et al., 2001) and, again, the upregulation of CB2 receptors might be interpreted as a defensive/protective mechanism to mediate immune response and suppression of inflammation. In parallel, the upregulation of CB2 receptors also demonstrate the tight link between alteration of CB2 signaling, immune dysfunction and ASD (Siniscalco et al., 2013). Remarkably, the enhancement of microglial phagocytic and migratory activity as well as the expression/activation of CB2 receptors are mechanisms involved in the anti-inflammatory effects and in the improvement of many ASD-like behaviors induced by the increase of PEA availability (Guida et al., 2017). Lower serum levels of not only PEA but also AEA and OEA have been detected in children with ASD (Aran et al., 2019), and both a reduction of mRNA levels of AEA-synthetizing enzyme NAPEPLD, and an upregulation of CB2 receptors have been disclosed in peripheral blood mononuclear cells (PBMCs) from ASD children (Siniscalco et al., 2013). There is evidence that PEA supplementation can improve some specific ASD symptoms, especially when supplemented as nutritional adjuvant to pharmacological treatment. Thus, the concomitant administration of the atypical antipsychotic risperidone and PEA was shown to reduce ASD-associated aberrant behaviors such as hyperactivity/irritability in a greater extent with respect to risperidone therapy only (Khalaj et al., 2018).

Hence, ASD etiology has a recognized immune dysfunction, microglia are brain resident immune cells that are found morphologically altered in ASD, and eCB signaling and microglia polarization mutually interact and modulate each other. From this view, is of particular interest the ASD-like mouse model of maternal immune activation (MIA) that appears suitable to test the hypotheses of early developmental and inflammatory adverse events in ASD etiology (Bilbo et al., 2018), which are in some studies described in association with alterations of microglia motility during gestational period (Ozaki et al., 2020) and abnormal microglia density (Hadar et al., 2017). The focus on the immune dysregulation in ASD and the use of models such as MIA and prenatal exposure to VPA, allow us to emphasize the importance of both heritable and environmental factors during critical developmental periods. Interestingly, microglia isolated from animals that underwent the VPA model of ASD showed high reactive morphology and increased resistance to stimulation-induced phagocytosis (Traetta et al., 2021). The postnatal administration of the non-psychoactive phytocannabinoid cannabidiol (CBDV) in rats underwent prenatal VPA exposure induced a recovery in the hippocampus of both glial fibrillar acidic protein (GFAP) and CD11b expression, as markers of astrocytes and microglia activation, respectively (Zamberletti et al., 2019). CBDV was also shown to relieve deficits in social behavior and hyperactivity and to upregulate hippocampal CB2 protein, thus supporting the possibility that CBDV-mediated
boosting of the eCB machinery might not only reduce neuroinflammation but also contribute to the recovery of microglia morphological changes and facilitate the shift towards the anti-inflammatory M2 phenotype (Zamberletti et al., 2019). Several maternal infections (e.g., herpes simplex virus type 2, cytomegalovirus) (Mahic et al., 2017; Slawinski

### TABLE 1 | Summary table of the key studies showing involvement of eCB signaling in ASD.

| eCB signaling in ASD | Subjects/System model | Major effects | Study |
|----------------------|-----------------------|---------------|-------|
| Circulating AEA, PEA and OEA | Children with ASD | Reduced serum levels unchanged ASD symptoms | Aran et al. (2019) |
| MAGL inhibition and increase of eCB signaling in BLA-NAc circuit | SHANK3 mouse model | Decreased deficits in social behavior and social avoidance | Folkes et al. (2020) |
| CBD-enriched oil | SHANK3 mouse model | Decreased ASD-like behavior (e.g., social anxiety) | Poleg et al. (2021) |
| CBD-enriched oil | Children with ASD | Improvement of symptoms (hyperactivity, social abilities) | Ponton et al. (2020), Loss et al. (2021), Bar-Lev Schleider et al. (2019) |
| PEA supplementation | Children with ASD | Improvement language skills | Antonucci et al. (2015) |
| Ultramicronized PEA + Luteolin coadministration | VPA-induced ASD-like mice | Improvement of social behavior | Bertolino et al. (2017) |
| Ultramicronized PEA + Luteolin coadministration | 10 year old male children | Stereotypies decrease improvement of ASD symptoms | Bertolino et al. (2017) |
| FAAH inhibition/increase of AEA-signaling | fmr1/FMRP KO mouse model/ASD-like BTBR mouse model | Reversion of social deficit (both models) | Wei et al. (2016) |
| Prenatal VPA exposure/effects in adolescent rats | ASD-like VPA rat model | Decreased DAGL-α activity/reduced 2-AG synthesis (cerebellum) Hippocampal enhancement of MAGL activity Social exposure induces AEA, PEA and OEA increase | Kerr et al. (2013) |
| Prenatal VPA exposure | ASD-like VPA rat model | Decrease of NAPE-PLD expression/Increase of AEA degradation/Deficits social play and communication | Servadio et al. (2016) |
| Pharmacological FAAH inhibition | ASD-like VPA rat model | Reduced VPA-induced deficits in social behavior | Kerr et al. (2016) |
| PBMCs | ASD patients | Up-regulation of CB2 receptors | Siniscalco et al. (2013) |
et al., 2018) or chronic inflammatory states (e.g., diabetes) (Xu et al., 2014) hitting the maternal environment increase the risk of ASD (Bilbo et al., 2018) and induce alterations of gut microbiota in the offspring, which may present an abnormal abundance of pro-inflammatory taxa (Ponzo et al., 2019). The dramatic effects induced by altered gut microbial composition on microglia homeostasis are well documented by the consequences of the lack of maternal gut microbiota (e.g., GM mice) on microglia maturation, development, mature morphology and function (Fung et al., 2017; Thion et al., 2018). In particular, it has been provided evidence that maternal gut microbiota can directly sculpt intrauterine microglia dynamics and development, and increase the presence of ramified microglial cells, a morphology generally mirroring a major “resting state” (Thion et al., 2018). Notably, this study also establishes that maternal gut microbiota can drive microglia function in the offspring in sex-specific manner. Indeed, while male offspring showed an altered microglia morphology during the embryonic phase, in female offspring the alterations were more evident during adulthood (Thion et al., 2018), thus underscoring the impact of maternal gut ecosystem for early microglia development in males and gender differences in ASD risk (Halladay et al., 2015). Here, we should consider the reduced ratio of Bacteroidetes to Firmicutes described in ASD subjects (De Angelis et al., 2013; Strati et al., 2017), and the further recently confirmed reduced level of Bacteroides fragilis induces recovery from social communication deficit and damage to intestinal permeability. The crosstalk between eCBs bioactive lipids and ASD is further supported by the shift of microglia towards an anti-inflammatory phenotype and improve of ASD symptoms following the increase of NAEs-mediated signaling.

**FIGURE 4 |** The figure portrays some key elements of the eCB signaling-gut microbiota-immune system crosstalk. Immune dysfunction can be a driving pathogenetic mechanism in ASD, with a strong deleterious impact on neuroinflammation, neurodevelopment and derangement of gut microbiota. Maternal immune activation (MIA) in pregnant mothers (A) and MIA-induced ASD-like mouse model (B) are both paradigmatic of increased ASD risk. Pathogens-induced deficits of systemic immune-regulation 1 provides an elevated level of explanation and isomorphism between ASD risk in humans and its simulation in mice. On the left panel (A), exposure to several types of infectious agents (e.g., herpes simplex virus type 2, cytomegalovirus) during pregnancy is responsible of immune activation and immune-regulatory deficits (e.g., auto-antibody production and/or increase of Th17 cells) as well as of the overproduction of maternal inflammatory cytokines (e.g., IL17A). Immune-regulatory dysregulation during pregnancy contributes to maternal dysbiosis and altered microbiota composition, with detrimental impact on fetal microglia motility and states of activation of microglial cells. The neuroinflammatory maternal and fetal environment elevates the risk of abnormal neurodevelopment and ASD diagnosis with offspring showing marked derangement of gut microbiota. On the right panel (B), the ASD-like MIA mouse model corroborates the hypothesis of early developmental and inflammatory adverse events in ASD etiology. Abnormal neurodevelopment, microglia morphological alterations and changes of offspring gut microbiota are common mechanisms in humans and mice models. Pro-inflammatory and immune challenges (e.g., Poly(I:C), LPS) trigger neurodevelopmental deficits in the offspring, with alteration of sociability and chronic neuroinflammation. For instance, microbiota segmented filamentous bacteria (SFB) produce an increase of Th17 activation (including IL17a production) but mice lacking SFB do not develop ASD-like symptoms. L. plantarum decreases SFB and supplementation with Bacteroides fragilis induces recovery from social communication deficit and damage to intestinal permeability. The crosstalk between eCBs bioactive lipids and ASD is further supported by the shift of microglia towards an anti-inflammatory phenotype and improve of ASD symptoms following the increase of NAEs-mediated signaling.

Coccurello et al. Endocannabinoids, Microbiota and ASD
may authorize to hypothesize that an increase of NAEs signaling and a shift of microglia phenotype may have a role in the recovery of ASD-like behaviors in models of immune dysregulation such as VPA and MIA. Moreover, if CBDV achieves its anti-inflammatory and prosocial behavioral effects after VPA exposure via the recovery of microglia morphological changes and through the upregulation of CB2 receptor in the hippocampus (Zamberletti et al., 2019), it should be noted that stimulation/upregulation of CB2 receptors is involved in the suppression of microglia activation (Ehrhart et al., 2005), in regulation of microglia recruitment and migration (Walter et al., 2003) as well as in the reduction of microglia-dependent release of pro-inflammatory factors and neurotoxicity (Komorowska-Müller and Schmölle, 2021). Hence, we might posit the existence of a vicious circle involving early immune dysfunction, microglia-driven neuroinflammation and neurotoxicity, alteration of gut microbiota and intestinal barrier integrity, disruption (generally reduced) of eCB- and CB2-mediated signaling and ASD pathogenesis. On the other side, to trigger an opposite virtuous circle both the administration of selected probiotics as well as non-psychoactive eCB compound and drugs capable to increase the activity of CB2 receptor may be considered together.

Alteration of maternal gut microbiota can be one pivotal mechanism responsible for MIA-induced alteration of sociability and neuroinflammation in the offspring (Kim et al., 2017). MIA-induced systemic inflammation and increase of interleukin-17a (IL-17a) plasma levels in pregnant mice has been in part ascribed to the activation of T helper 17 (Th17) cells, whose intestinal biogenesis is strongly stimulated by commensal organism known as segmented filamentous bacteria (SFB) (Farkas et al., 2015; Kim et al., 2017). Interestingly, mice lacking SFB did not develop MIA-induced ASD-like behavior and did show neither cortical alterations nor plasma increase in IL-17a levels. Thus, not only intestinal accumulation of SFB during pregnancy is detrimental for MIA-induced behavioral phenotype in the offspring, but the excessive differentiation of gut Th17 cells may increase the risk of a progeny with ASD. Abnormal Th17 activity and consequent IL-17 production are linked to multiple inflammatory, neurological and autoimmune diseases (Waite and Skokos, 2012; Milovanovic et al., 2020), and AEA, D9-THC and CBD treatment has shown efficacy against different Th17-driven diseases (Kozela et al., 2013; Jackson et al., 2014). In particular, eCBs are involved in the modulation of immune function and an increase of AEA signaling has been shown to suppress Th17-driven inflammation evoked by methylated Bovine Serum Albumin-induced delayed type hypersensitivity response via the upregulation of IL-10 secretion (Jackson et al., 2014). Other data in support of the involvement of eCBs in Th17-driven diseases have been provided for the suppressive effects obtained by THC and, above all, CBD administration upon IL-17 and IL-6 secretion, which has also been demonstrated to reduce the Th17-induced cell phenotype (Kozela et al., 2013). As observed, Clostridium genus is frequently found abundant in gut microbiota of subjects with ASD (Finegold et al., 2010; de Angelis et al., 2015) and Clostridium-derived metabolites [e.g., 3-(3-hydroxyphenyl)-3-hydroxypropionic acid] can be found elevated in urine samples from ASD patients (Shaw, 2010). Interestingly, based on gene sequence similarity, SFB are closely related to the Clostridium genus and their abnormal increase in the ileum of immunocompromised mice has been found counteracted by Lactobacillus plantarum administration (Fuentes et al., 2008). If SFB expression in the intestine epithelium stimulates Th17 cells development and contribute to the risk of ASD (Kim et al., 2017) but potentiation of eCB signaling is effective against Th17-driven diseases (Kozela et al., 2013; Jackson et al., 2014), then it is of further relevance that administration of Lactobacillus plantarum reduces SFB presence (Fuentes et al., 2008) and that Lactobacillus plantarum was included in the same probiotic mix observed to increase the expression of Cnr1 and Cnr2 genes in zebrafish intestinal epithelium (Gioacchini et al., 2017). Lastly, Lactobacillus plantarum administration was shown to normalize 2-AG hippocampal level in a mouse model of depression, and the restoration of the integrity of eCB signaling was accompanied by the renewal of hippocampal neurogenesis and alleviation of depressive-like behaviors (Chevalier et al., 2019).

Thus, paradigmatic of the role of immune system not only as a link between gut microbiota and alteration of neurodevelopment in the offspring, but also of the possible overlapping mechanisms and reciprocal influence between eCB signaling and gut microbial ecology is the MIA construct. Some of these connections and few notions illustrated in this third chapter are exemplified in Figure 4. We mentioned before the dramatic changes of microglia maturation, density and/or morphology when gut microbiota underwent dysbiosis or reduced microbial diversity (Fung et al., 2017; Thion et al., 2018). However, despite the accumulating evidence in support of microbiota-microglia crossstalk, much less is known about the molecular messengers carrying to microglia the information concerning microbiota status. A potential answer to this issue has been provided by the demonstration that oral supplementation with a mix of SCFAs in GM mice produced a normalization of microglia in brain cortex (i.e., density stabilization) and a decrease of aberrant morphology and immaturity (Erny et al., 2015). Moreover, sodium butyrate treatment has been shown to put out the inflammation’s fire in brain-derived primary microglial cells after LPS challenge (Huuskonen et al., 2004), as well as more recently the administration of a SCFAs mixture was shown to decrease microglia-derived secretion of cytokines and cytotoxins relevant for Alzheimer’s disease pathogenesis (Wenzel et al., 2020). Hence, on this ground, SCFAs appear valid candidates as microbial metabolites carrying information from microbiota to microglial cells both for defense and upkeeping of microglia status. However, within the context of the present evaluation, it would also be particularly important to ascertain whether specific gut bacteria strains and/or microbial metabolites could affect eCB signaling. Well, the answer appears to be affirmative both for selected bacteria strains and SCFAs, and for butyrate in particular. As mentioned before, probiotics may trigger the intestinal
expression of eCB receptors, and *Lactobacillus acidophilus* treatment was able to induce CNR2 mRNA expression on human epithelial cells. (Rousseaux et al., 2007). Indeed, oral administration in rats of *L. acidophilus* induced the expression of functional CB2 receptors, as corroborated by the fact that *L. acidophilus*-mediated analgesic effects were inhibited by CB2 receptors blockade (Rousseaux et al., 2007). SCFAs display anti-inflammatory activity, and a significant part of such activity is attributable to changes of eCB signaling. This is the main conclusion of a recent population study (Vijay et al., 2021) investigating the interaction between gut microbiota and eCB system in the secretion of well-characterized markers of inflammation. Interestingly, physical exercise was used to stimulate the growth of SCFA-producing bacteria, and by a formal analysis was possible to ascertain that physical exercise increased AEA, OEA and PEA, and that for instance AEA mediated about 30% of the effects of butyrate on TNF-α together with a positive association between 2-AG and OEA and anti-inflammatory cytokines such as IL-10. Additionally, the fact that both AEA and OEA were found positively correlated with SCFAs receptor expression (i.e., FFAR2 receptor) is a critical evidence that the eCB system shapes microbiota composition and mediates part of the anti-inflammatory effects elicited by SCFA microbial mediators (Vijay et al., 2021). Several key studies discussed all along chapter 3 are summarized in Table 2.

### 3.1 Summary and Conclusion

As for the understanding of neurodegenerative diseases (Armstrong, 2014), causes and effects are tightly intertwined in ASD, and no conclusive statements can be made on the primary or causal events underlying the eCBs-microbiota partnership in ASD etiology. Indeed, in spite of the considerable body of investigation, our current knowledge does not allow to determine whether the disruption of microbial ecosystem could be considered a primary event causing derangement of eCB signaling or, *vice-versa*, whether the unbalance of eCB system might trigger the disruption of gut microbiota diversity described in ASD patients. The aspects so far examined might support both the lines of cause-effect relationship, thus either that a “major” gut derangement of microbial population produces downstream abnormal changes of eCB signaling and ASD-associated brain alterations (e.g., microglia-dependent neuroinflammation), or that dyshomeostasis of the eCB system contributes to alteration of gut microbial composition. Nevertheless, if the current updated appraisal of the endocannabinoids-gut microbiota partnership in ASD pathophysiology has provided sufficient evidence, this is a no way-out thinking.

Instead, adding the factor “eCB signaling” to the equation “ASD and gut microbiota” should help to disclose the role of eCB system as one of the major factors responsible of brain homeostasis. Loss of control exerted by the eCB system and ASD-associated abnormal variations in AEA, 2-AG and NAEs are factors that can help to fill the empty space between neurodevelopment, gut microbiota and brain inflammation. We reported extensive evidence (e.g., paragraphs in Sections 1.2, 2.1, and 2.3) according to which ASD can be viewed as a NDD with a prominent state of brain inflammation and immune dysfunction. The detailed description of altered composition of intestinal microbiota in ASD-like models such as SHANK3, MIA, BTBR and VPA exposure provides several turning points where the study of the relationship between gut ecosystem and eCB signaling can be more elaborated.

Here, only a list of selected key evidence is reported, namely: 1) the recovery of social behavior in the Shank3B+/mice is achieved by the increase of 2-AG mediated eCB signaling (via MAGL inhibition) or CBD-enriched cannabis oil (Folkes et al., 2020; Poleg et al., 2021); 2) the abnormal increase of selective bacteria family (e.g., *Erysipelotrichaceae*) in ASD patients with lower oxytocin levels and the parallel decrease of *Lactobacillaceae* and *Erysipelotrichaceae* families in animals with increased levels of 2-AG and 2-MAGs (Dione et al., 2020); 3) the possibility to predict eCBs changes such as PEA faecal levels through microbiota diversity (Minichino et al., 2021); 4) the association between gut permeability improvement, *A. muciniphila* supplementation, increase of 2-AG and 2-AcGs family intestinal levels (Everard et al., 2013; Depommier et al., 2021) and decreased *A. muciniphila* abundance in ASD children (Wang et al., 2011); 5) the beneficial effects of PEA supplementation on neuroinflammation and social behaviors in ASD-like BTBR mouse model (Cristiano et al., 2018); 6) the possibility to counteract social deficit by increasing AEA signaling both in FXS (i.e., *fmr1* knockout mouse) and BTBR models of ASD-like behavior (Wei et al., 2016); 7) the evidence for reduced DAGL1 activity and increase of 2-AG degradation in the neurodevelopmental VPA model (Kerr et al., 2013); 8) the increase AEA degradation following exposure to VPA (Servadio et al., 2016) and the mitigation of social communication deficits after FAAH inhibition in the same model (Kerr et al., 2016); 9) the possibility to increase colon expression of CB2 receptor mRNA after *L. acidophilus* supplementation (Rousseaux et al., 2007) mirroring the upregulation of CB2 receptors in PBMCs of ASD subjects (Siniscalco et al., 2013); 10) the possibility to increase the intestinal mRNA expression of *Cnr1* and *Cnr2* genes as well as decrease of *faah* and *mgl* gene expression after *B. longum, L. acidophilus* and *Bifidobacterium infantis* supplementation (Gioacchini et al., 2017); 11) the existence of a functional interaction between eCB signaling, vitamin D metabolism, and changes in gut microbiota in ASD (Su et al., 2016; Guida et al., 2020; Morsanuto et al., 2020) 12) the ability of selected probiotics such as *B. infantis* to improve KP metabolism (Desbonnet et al., 2008), and also stimulate the expression of *Cnr1* and *Cnr2* genes in zebrafish intestinal epithelium (Gioacchini et al., 2017) and improve autistic core symptoms (Grossi et al., 2016); 13) the microglia alterations in density and morphology observed in ASD patients and ASD-like MIA mouse model (Hadar et al., 2017; Bilbo et al., 2018), and the possibility to recover social behavior, microglia activation and M2 phenotype by enhancing the eCB machinery; 14) the fact that intestinal SFB expression stimulates T_{H}17 cells and increase...
TABLE 2 | Summary table of the key studies involving eCB signaling and gut microbiota crosstalk in both patients with ASD and ASD-like animal models.

| eCB signaling-microbiota partnership in ASD | Subjects/System model | Major effects | Study |
|--------------------------------------------|------------------------|---------------|-------|
| **Gut microbiota dysbiosis** | **Lactobacillus acidophilus supplementation** | Human HT-29 epithelial cells | Dysregulates the intestinal eCB system Increased intestinal cells CB2 receptor mRNA expression | Rousseaux et al. (2007) |
| **eCB and PEA faecal levels** | | General population | Prediction of the association between gut microbial diversity and anhedonia | Minichino et al. (2021) |
| **Prebiotic treatment: mucin-degrading Gram-negative bacterium** | Children with ASD | *A. muciniphila* supplementation improves gut permeability/increases 2-AG intestine levels | Everard et al. (2013) |
| **Prebiotic treatment: mucin-degrading Gram-negative bacterium** | Children with ASD | *A. muciniphila* supplementation provides beneficial effects dependent on eCB-derived lipids of the 2-AcGs family | Depommier et al. (2021) |
| **Mucin-degrading Gram-negative bacterium** | Children with ASD | Decreased *A. muciniphila* abundance | Wang et al. (2011) |
| **Mucin-degrading Gram-negative bacterium** | Children with ASD | Increased *A. muciniphila* abundance | De Angelis et al. (2013) |
| **Ultramicronized PEA + Luteolin coadministration** | ASD-like BTBR mouse model | Decreased ASD-like repetitive behavior/pro-inflammatory cytokine production/intestinal permeability/increased sociability | Cristiano et al., (2018) |
| **B. longum probiotic mix (including *Lactobacillus acidophilus* and *B. infantis*) supplementation** | Zebrafish | Increase intestinal mRNA expression of Cnr1 and Cnr2 genes Decrease of faah and mgl gene expression | Gioacchini et al. (2017) |
| **B. fragilis supplementation** | ASD-like MIA model | Improves social-communicative deficits/integrity intestinal barrier | Hsiao et al. (2013) |
| **Bifidobacterium longum** | Children with ASD | ASD depletion of *B. longum* Decrease butyrate-producing bacteria | Coretti et al. (2018), Sugahara et al. (2015) |
| **Butyrate treatment** | ASD-like VPA and BTBR models | Improvement memory and social behavior | Takuma et al. (2014), Kratsman et al. (2016) |
| **Butyrate and butyrate-producing bacteria** | Children with ASD | Lower levels of butyrate and abundance of Lachnospiraceae | Liu et al. (2013) |
| **Butyrate treatment (concentration-dependent effects)** | Epithelial cell line Caco-2 | Decrease eCBs synthetizing enzymes (i.e., NAPE-PLD, DAGL) | Hwang et al. (2021) |

(Continued on following page)
TABLE 2 | (Continued) Summary table of the key studies involving eCB signaling and gut microbiota crosstalk in both patients with ASD and ASD-like animal models.

| eCB signaling-microbiota partnership in ASD | Subjects/System model | Major effects | Study |
|---------------------------------------------|-----------------------|--------------|-------|
| eCB system and signaling                    | Children with ASD vs ASD-like VPA murine model | eCB signaling FAAH and MAGL increased expression Decrease of 2-AG serum levels | Zou et al. (2021) |
| Vitamin D                                   | Vitamin D deficiency pregnancy Vitamin D supplementation | Risk of ASD Improve expression ASD symptoms | Lee et al. (2021) Principi and Esposito (2020) |
| PEA and vitamin D                           | Epithelial cell line Caco-2 | CB2 receptor activation | Morsanuto et al. (2020) |
| Microglial cells morphology                 | ASD subjects | Changes in microglial cells phenotype (e.g., decreased ramified microglia) | Lee et al. (2017) |
| PEA availability                            | Primary microglia cell culture | Increase microglial phagocytic/Migratory activity | Guida et al. (2017) |
| CBDV supplementation                        | ASD-like VPA murine model | Microglia activation/Decrease deficit social behavior/Upregulation CB2 RS | Zamberletti et al. (2019) |
| Bacteroides                                 | ASD subjects | Reduced levels | Cao et al. (2021) |
| Bacteroides                                 | eCB-like production | High affinity GPR119 (2-OG and OEA) | Cohen et al. (2017) |
| Systemic inflammation                       | ASD-like MIA murine mice Mice lacking SFB | Segmented filamentous bacteria (SFB) promotes TH17 intestinal biogenesis TH17-induced increase IL17-a plasma levels Failure of MIA-induced ASD-like symptoms | Farkas et al. (2015) Kim et al. (2017) |
| AEA, Δ9-THC, CBD administration             | TH17-driven diseases | Microglia activation/Decrease deficits social behavior/Upregulation CB2 Rs | Kozela et al. (2019), Jackson et al. (2014) |

(Continued on following page)
Fuentes et al. (2008) and decreases SFB presence and contribute to the expression of the astrogial CB1 receptors and lactate by focusing the study on astroglial CB1 receptors and lactate ASD pathogenesis (Gzielo and Nikiforuk, 2021), and in particular the eCB receptor GPR119 (Cohen et al., 2017).

Physical exercise SCFAs supplementation Gut microbiota-eCB system interaction Decrease SFB abundance Increase SCFA-dependent AEA, OEA and PEA levels AEA and OEA correlation with SCFAs receptor expression Fuentes et al. (2008) Vijay et al., (2021)

ASD risk (Kim et al., 2017) but enhancement of eCB signaling improves T117-driven diseases (Kozela et al., 2013; Jackson et al., 2014) and Lactobacillus plantarum administration decreases SFB presence and contribute to the expression of Cnr1 and Cnr2 genes (Gioacchini et al., 2017); 15) the fact that SCFA-producing bacteria are stimulated by physical exercise and that the parallel increase of AEA, OEA and PEA mediate the butyrate-dependent effects on anti-inflammatory activity (Vijay et al., 2021); 16) lastly, the fact that selected gut microbiota bacteria (e.g., Bacteroides) have been found capable to produce eCB-like molecules such as commendamide (N-acetyl-3-hydroxypalmitoyl-glycine), which is an agonist at GPR132 (Cohen et al., 2015), and N-oleoylserinol that is an agonist of the eCB receptor GPR119 (Cohen et al., 2017).

Finally, a still unexplored area of investigation might emerge from the more extensive understanding of the role of astrocytes in ASD pathogenesis (Gzielo and Nikiforuk, 2021), and in particular by focusing on the astroglial CB1 receptors and lactate signaling in astrocyte-neuron communication (i.e., astrocyte-neuron lactate shuttle, ANLS) as well as on the perturbation of lactate levels and the alterations of lactate-producing bacteria in gut microbiota of subjects with ASD. There is indeed evidence that these aspects could be re-examined at the light of their functional relationship with the ASD pathophysiology. Lactate is known to act not only as signaling molecule between astrocytes and neurons where is required to meet energy needs and maintain brain homeostasis (i.e., metabolic coupling and ANLS) (Pellerin and Magistretti, 1994; Mason, 2017), but also as signaling molecule involved in memory formation (Suzuki et al., 2011) and in schizophrenia-like aberrant behavior (Sun et al., 2021).

Several clinical surveys report higher blood lactate levels and higher lactate-to-pyruvate ratio in ASD (Oh et al., 2020), which are biochemical changes that could at least in part attributed to the dysregulation of the WNT/β-catenin pathway (Vallée and Vallée, 2018) and/or to reduction of gut bacteria responsible for lactate fermentation such as the decrease of Veillonellaceae described in subjects with ASD (Kang et al., 2013). Moreover, in some cases, the higher presence of lactate-producing bacteria might contribute to the reduction of SCFAs levels, and in particular of butyrate, whose consequences (e.g., inflammation susceptibility) have been emphasized earlier. Although with important exceptions (Coretti et al., 2018), in ASD has been reported not only a reduction of SCFA- and butyrate-producing bacteria, but in particular a reduction of the genera Anaerostipes and Eubacterium, (Liu et al., 2019; Cao et al., 2021), which are both essential for lactate-to-SCFAs conversion and prevention of lactate accumulation (Duncan et al., 2004).

In conclusion, the idea that gut microbiota can determine and underlie ASD pathophysiology is increasingly accepted, and in this critical review we have provided extensive evidence for gut dysbiosis, reduced microbial diversity, increased inflammation of gut epithelium, selective derangement of microbial population and gut ecosystem in ASD patients, aberrant immune profile, role of SCFAs and microbiota-derived metabolites and effects of probiotic intervention. In parallel, we discussed the literature focused on the emerging issue of the involvement of the eCB machinery in ASD and ASD-associated alterations of social behavior, as well as on the demonstration in ASD patients and in ASD-like animal models of a general decline in eCB signaling, and the potential therapeutic applications thereof in terms of both achievements and failures. A great attention has been addressed to the perspective to consider together the two aspects, and the possibility that the eCBs-microbiota partnership might offer novel pathways of investigation and synergistic options for therapeutic intervention, both pharmacological and nutritional, especially with the aim to improve the quality of life of patients and their caregivers.

**AUTHOR CONTRIBUTIONS**

RC and MM conceived the study; RC wrote the manuscript, which was revised by MM. MCM prepared the artwork, and critically read the manuscript.

**FUNDING**

This paper was made possible by partial financial support from Ministero dell’Istruzione, dell’Università e della Ricerca under competitive PRIN 2017 grant no. 2017BTHJ4R to MM, and from Università degli Studi dell’Aquila under intramural competitive grants “RIA 2021” and “Progetti di Ricerca di Ateneo 2021” to MM.
ACKNOWLEDGMENTS

The authors wish to thank all their collaborators who contributed over the years to their studies on the endocannabinoid system and its impact on human health and disease.

REFERENCES

Abbeduto, L., McDuffie, A., and Thurman, A. J. (2014). The Fragile X Syndrome-Autism Comorbidity: What Do We Really Know? Front. Genet. 5, 355. doi:10.3389/genet.2014.00355

Adams, J. B., Johansen, L. J., Powell, L. D., Quig, D., and Rubin, R. A. (2011). Gastrointestinal Flora and Gastrointestinal Status in Children with Autism-Comparisons to Typical Children and Correlation with Autism Severity. BMC Gastroenterol. 11, 22. doi:10.1186/1471-230X-11-22

Ahern, G. P. (2003). Activation of TRPV1 by the Satiey Factor Oleoylethanolamide. J. Biol. Chem. 278, 30429–30434. doi:10.1074/jbc.M305051200

Al-Salem, H. S., Bhat, R. S., Al-Ayadhi, L., and El-Ansary, A. (2016). Therapeutic Potency of Bee Pollen against Biochemical Autistic Features Induced through Acute and Sub-acute Neurotoxicity of Orally Administered Proionic Acid. BMC Comp. Altern. Med. 16, 120. doi:10.1186/s12906-016-1099-8

Alveim, A. R., Malde, M. K., Osei-Hyiaman, D., Lin, Y. H., Pawlowski, R. J., Madsen, L., et al. (2012). Dietary Linoleic Acid Elevates Endogenous 2-AG and Anandamide and Induces Obesity. Obes. (Silver Spring) 20, 1984–1994. doi:10.1038/oby.2012.38

Alveim, A. R., Torstensen, B. E., Lin, Y. H., Lillefosse, H. H., Lock, E. J., Madsen, L., et al. (2014). Dietary Linoleic Acid Elevates the Endocannabinoids 2-AG and Anandamide and Promotes Weight Gain in Mice Fed a Low Fat Diet. Lipids 49, 59–69. doi:10.1007/s11745-013-3842-y

Alveim, A. R., Torstensen, B. E., Lin, Y. H., Lillefosse, H. H., Lock, E. J., Madsen, L., et al. (2013). Dietary Linoleic Acid Elevates Endogenous 2-arachidonoylglycerol and Anandamide in Atlantic Salmon (Salmo salar L.) and mice, and induces weight gain and inflammation in mice. Br. J. Nutr. 109, 1508–1517. doi:10.1017/s0007114512003364

American Psychiatric Association (2013). “Diagnostic and Statistical Manual of Mental Disorders,” in (DSM-5). Diagnostic Stat. Man. Ment. Disord. 4th Ed. TR 5th Edition. doi:10.1176/appi.books.987089042359674053

American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (2012). American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Indian J. Psychiatry. 55, 220–223. doi:10.4103/0019-5545.97966

Antonacci, N., Cirillo, A., and Siniscalco, D. (2015). Beneficial Effects of Palmitoylethanolamide on Expressive Language, Cognition, and Behaviors in Autism: A Report of Two Cases. Case Rep. Psychiatry 2015, 1–6. doi:10.1155/2015/325061

Aran, A., Eylon, M., Harel, M., Polianski, L., Nemirovski, A., Tepper, S., et al. (2019). Lower Circulating Endocannabinoid Levels in Children with Autism Spectrum Disorder. Mol. Autism 10, 2. doi:10.1186/s13229-019-0256-6

Armstrong, R. A. (2014). A Critical Analysis of the ‘amyloid Cascade Hypothesis’. Folia Neuropathol. 52, 211–225. doi:10.5111/FN.2014.45562

Atalay, S., Jarocka-karpowicz, I., and Skrzylewksa, E. (2020). Antioxidative and Anti-inflammatory Properties of Cannabidiol. Antioxidants (Basel) 9. doi:10.3390/antiox9010021

Bailey, D. B., Raspa, M., Olmsted, M., and Holiday, D. B. (2008). Co-occurring Conditions Associated with FMR1 Gene Variations: Findings from a National Parent Survey. Am. J. Med. Genet. A 146A, 2060–2069. doi:10.1002/ajmg.a.32439

Banni, S., Carta, G., Murrù, E., Cordeddu, L., Giordano, E., Sirigu, A. R., et al. (2011). Krill Oil Significantly Decreases 2-arachidonoylglycerol Plasma Levels in Obese Subjects. Nutr. Metab. (Lond.) 8, 7. doi:10.1186/1743-7075-8-7

Bar-Lev Schleider, L., Mechoulam, R., Sahab, N., Meiri, G., and Novack, V. (2019). Real Life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy. Sci. Rep. 9, 200. doi:10.1038/s41598-018-37570-y

Bonacci, L., Lauri, M., Sarasua, S. M., Skinner, C. D., Buccella, D., Dwivedi, A., et al. (2013). Prevalence of SHANK3 Variants in Patients with Different Subtypes of Autism Spectrum Disorders. Eur. J. Hum. Genet. 21, 310–316. doi:10.1038/ejhg.2012.175

Benito, C., Núñez, E., Tolón, R. M., Fiallo, J. E., Rábano, A., Hillard, C. J., et al. (2003). Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer’s Disease. J. Neurosci. 23, 11136–11141. doi:10.1523/jneurosci.23-35-11136.2003

Benito, C., Tolón, R. M., Pasos, M. R., Núñez, E., Castillo, A. I., and Romero, J. (2008). Cannabinoid CB2 Receptors in Human Brain Inflammation. Br. J. Pharmacol. 153, 277–285. doi:10.1038/sj.bjp.0707505

Bilbo, S. D., Block, C. L., Bolton, J. L., Hanamsagar, R., and Tran, P. K. (2018). Beyond Infection - Maternal Immune Activation by Environmental Factors, Microglial Development, and Relevance for Autism Spectrum Disorders. Exp. Neurol. 299, 241–251. doi:10.1016/j.expneurol.2017.07.002

Bissog, T., Hanus, L. J., De Petrocellis, L., Tchilibon, S., Ponde, D. E. B., Brandi, L., et al. (2001). Molecular Targets for Cannabidiol and its Synthetic Analogues: Effect on Vanilloid VR1 Receptors and on the Cellular Uptake and Enzymatic Hydrolysis of Anandamide. Br. J. Pharmacol. 134, 845–852. doi:10.1038/sj.bjp.0704327

Boccuto, L., Lauri, M., Sarasua, S. M., Skinner, C. D., Buccella, D., Dwivedi, A., et al. (2015). Palmitoylethanolamide, a Naturally Occurring Lipid, Is an Orally Effective Intestinal Anti-inflammatory Agent. Br. J. Pharmacol. 172, 142–158. doi:10.1111/bph.12907

Brown, J. D., McAnally, D., Ayala, J. E., Burmeister, M. A., Morfa, C., Smith, L., et al. (2018). Oleoylethanolamide Modulates Glucagon-like Peptide-1 Receptor Agonist Signaling and Enhances Exendin-4-Mediated Weight Loss in Obese Mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 315, R595. doi:10.1152/ajpregu.00459.2017

Buffington, S. A., Di Prisco, G. V., Auchting, T. A., Ajami, N. J., Petrosino, J. F., and Costa-Mattioli, M. (2016). Microbial Reconstitution Reverses Maternal Diet-Induced Social and Synaptic Deficits in Offspring. Cell 165, 1762–1775. doi:10.1016/j.cell.2016.06.001

Burcelin, R. (2016). Gut Microbiota and Immune Crosstalk in Metabolic Disease. Mol. Metab. 5, 771–781. doi:10.1016/j.molmet.2016.05.016

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.869606/full#supplementary-material
Alterations of Intestinal Endocannabinoid Signaling. J. Lipid Res. 61, 70–85. doi:10.1194/jlr.RA119004234
Mancini, C., Shen, M., Boubertakh, B., Martin, C., Flamand, N., Silvestri, C., et al. (2020b). Alterations of Brain Endocannabinoid Signaling in Germ-free Mice. Biochimica Biophysica Acta (BBA) - Mol. Cell Biol. Lipids 1865, 158786. doi:10.1016/j.bbalip.2020.158786
Marco, E. M., Sapino, C., Borsini, F., Maccarrone, M., and Laviola, G. (2011). Social Encounter with a Novel Partner in Adolescent Rats: Activation of the Central Endocannabinoid System. Behav. Brain Res. 220, 140–145. doi:10.1016/j.bbr.2011.01.044
Marrone, C., and Coccorello, R. (2019). Dietary Fatty Acids and Microbiota-Brain Communication in Neuropsychiatric Diseases. Biomolecules 10, 12. doi:10.3390/biom10010012
Mason, S. (2017). Lactate Shuttles in Neuroenergetics-Homeostasis, Allostasis and beyond. Front. Neurosci. 11, 43. doi:10.3389/fnins.2017.00043
Massiera, F., Barbry, P., Guesnet, P., Joly, A., Luquet, S., Moreillon-Brest, C., et al. (2010). A Western-like Fat Diet Is Sufficient to Induce a Gradual Enhancement in Fat Mass over Generations. J. Lipid Res. 51, 2352–2361. doi:10.1194/jlr.M008686
Matias, I., and Di Marzo, V. (2006). Endocannabinoid System and its Role in Energy Regulation. Expert Rev. Endocrinol. Metab. 1, 557–569. doi:10.1586/17446551.1.4.557
Matijas, M., Meltròvic, T., Paljetak, H. Ć., Perić, M., Baresić, A., and Verbanac, D. (2020). Gut Microbiota beyond Bacteria-Mycobiome, Virome, Archaeome, and Eukaryotic Parasites in IBD. Int. J. Mol. Sci. 21. doi:10.3390/ijms21082686
Mattace Raso, G., Russo, R., Calignano, A., and Meli, R. (2014). Palmitoylethanolamide in CNS Health and Disease. Pharmacol. Res. 86, 32–41. doi:10.1016/j.phrs.2014.05.006
McGrath, J. J., Burne, T. H., Bérubé, T. H., Feron, F., Burne, T. H., et al. (2021). Endocannabinoid System Mediate the Enhancement of Amyloid-Beta-Induced and Age-Associated Changes in Rat Hippocampus by Eicosapentaenoic Acid. J. Neurochem. 103, 914–926. doi:10.1111/j.1471-4159.2007.04848.x
Moranis, A., Delpech, J. C., De Smelt-Peyrusse, V., Aubert, A., Guesnet, P., Lavillie, M., et al. (2012). Long Term Adequate N-3 Polyunsaturated Fatty Acid Diet Protects from Depressive-like behavior but Not from Working Memory Disruption and Brain Cytokine Expression in Aged Mice. Brain. Behav. Immun. 26, 721–731. doi:10.1016/j.bbi.2011.11.001
Morrison, D. J., and Preston, T. (2016). Formation of Short Chain Fatty Acids by the Gut Microbiota and Their Impact on Human Metabolism. Gut Microbes 7, 189–200. doi:10.1080/19490976.2015.1134082
Morsanuto, V., Galla, R., Molinari, C., and Uberti, F. (2020). A New Palmitoylethanolamide Form Combined with Antioxidant Molecules to Improve its Effectiveness on Neuronal Aging. Brain Sci. 10, 457–477. doi:10.3390/brainsci10070457
Murataeva, N., Dhopeshwarkar, A., Yin, D., Mitjavila, J., Bradshaw, H., Straker, A., et al. (2016). Where’s My Entourage? The Curious Case of 2-oleoylglycerol, 2-linoleoylglycerol, and 2-palmitoylglycerol. Pharmacol. Res. 110, 173–180. doi:10.1016/j.phrs.2016.04.015
Navarrete, F., García-Gutiérrez, M. S., Jurado-Barba, R., Rubio, G., Gasparyan, A., Autschich-Olivares, A., et al. (2020). Endocannabinoid System Components as Potential Biomarkers in Psychiatry. Front. Psychiatry 11, 315. doi:10.3389/fpsyt.2020.00315
Navarra, A., Tamburella, A., Iannotti, F. A., Micale, V., Camilleri, G., Gozzo, L., et al. (2014). The Dual Blocker of FAAH/TRPV1 N-Arachidonoylserotonin Reverses the Behavioral Deficit Induced by Stress in Rats and Modulates the HPA-axis. Pharma. Res. 87, 151–159. doi:10.1007/s11095-014-1897-z
Nickel, K., Maier, S., Endres, D., Joos, A., Maier, V., Tebartz van Elst, L., et al. (2019). Systematic Review: Overlap between Eating, Autism Spectrum, and Attention-Deficit/Hyperactivity Disorder. Front. Psychiatry 10, 708. doi:10.3389/fpsyt.2019.00708
Niesink, R. J., and van Laar, M. W. (2013). Does Cannabidiol Protect against Adverse Psychological Effects of THC? Front. Psychiatry 4, 130. doi:10.3389/fpsyt.2013.00130
Oh, M., Kim, S. A., and Yoo, H. J. (2020). Higher Lactate Level and Lactate-To-Pyruvate Ratio in Autism Spectrum Disorder. Exp. Neurobiol. 29, 314–322. doi:10.5607/en.202003
Onore, C., Careaga, M., and Ashwood, P. (2012). The Role of Immune Dysfunction in the Pathophysiology of Autism. Brain. Behav. Immun. 26, 383–392. doi:10.1016/j.bbi.2011.08.007
Overtorn, H. A., Babbs, A. J., Doel, S. M., Fyfe, M. C., Gardner, L. S., Griffin, G., et al. (2006). Deorphanization of a G Protein-Coupled Receptor for Oleoylethanolamide and its Use in the Discovery of Small-Molecule Hypagentic Agents. Cell Metab. 3, 167–175. doi:10.1016/j.cmet.2006.02.004
Ozaki, K., Kato, D., Ikegami, A., Hashimoto, A., Sugio, S., Guo, Z., et al. (2020). A New Endocannabinoid Anandamide Derivative for Parkinson’s Disease. Mol. Psychiatry 26, 140. doi:10.1038/s41380-020-07829-4
Passani, M. B., and Coccorello, R. (2016). “The Endocannabinoid-like Derivative Oleoylethanolamide at the Gut-Brain Interface: A ‘Lipid Way’ to Control Energy Intake and Body Weight,” in Cannabinoids in Health and Disease. doi:10.5772/63147
Paterniti, I., Impellizzeri, D., Crupi, R., Morabito, R., Campolo, M., Esposto, E., et al. (2013). Molecular Evidence for the Involvement of PPAR-β and PPAR-γ in Anti-inflammatory and Neuroprotective Activities of Palmitoylethanolamide after Spinal Cord Trauma. J. Neuroinflammation 10, 20. doi:10.1186/1742-2094-10-20
Patzke, C., Dai, J., Brockmann, M. M., Sun, Z., Fenske, P., Rosenmund, C., et al. (2021). Cannabinoid Receptor Activation Acutely Increases Synaptic Vesicle Numbers by Activating Synapses in Human Synapses. Mol. Psychiatry 26, 6253–6268. doi:10.1038/s41380-021-01095-0
Zamberletti, E., Gabaglio, M., and Parolaro, D. (2017). The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models. *Int. J. Mol. Sci.* 18. doi:10.3390/ijms18091916

Zamberletti, E., Gabaglio, M., Woolley-Roberts, M., Bingham, S., Rubino, T., and Parolaro, D. (2019). Cannabidivarin Treatment Ameliorates Autism-like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats. *Front. Cell. Neurosci.* 13, 367. doi:10.3389/FNCEL.2019.00367

Zheng, D., Liwinski, T., and Elinav, E. (2020). Interaction between Microbiota and Immunity in Health and Disease. *Cell Res.* 30, 492–506. doi:10.1038/s41422-020-0332-7

Zou, M., Liu, Y., Xie, S., Wang, L., Li, D., Li, L., et al. (2021). Alterations of the Endocannabinoid System and its Therapeutic Potential in Autism Spectrum Disorder. *Open Biol.* 11, 200306. doi:10.1098/RSOB.200306

Zucker, N. L., Losh, M., Bulik, C. M., LaBar, K. S., Piven, J., and Pelphrey, K. A. (2007). Anorexia Nervosa and Autism Spectrum Disorders: Guided Investigation of Social Cognitive Endophenotypes. *Psychol. Bull.* 133, 976–1006. doi:10.1037/0033-2909.133.6.976

**Conflict of Interest:** The authors declare that the study was conducted in the absence of any commercial or financial relationships that could be viewed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Copyright © 2022 Coccurello, Marrone and Maccarrone. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**